3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Lymphoma
17
Leukemia, Myeloid, Acute
16
Breast Neoplasms
15
Precursor Cell Lymphoblastic Leukemia-Lymphoma
14
Multiple Myeloma
12
Lymphoma, Large B-Cell, Diffuse
12
Lymphoma, Non-Hodgkin
11
Carcinoma, Non-Small-Cell Lung
11
Lymphoma, Mantle-Cell
10
Leukemia
10
Lymphoma, Follicular
9
Hodgkin Disease
9
Myelodysplastic Syndromes
8
Recurrence
7
Neuroblastoma
7
Neoplasm Metastasis
7
Leukemia, Lymphocytic, Chronic, B-Cell
7
Brain Neoplasms
7
Neoplasms, Plasma Cell
6
Lymphoma, B-Cell, Marginal Zone
6
Lung Neoplasms
6
Glioblastoma
6
Prostatic Neoplasms
5
Pancreatic Neoplasms
5
Lymphoma, T-Cell, Cutaneous
5
Lymphoma, T-Cell
5
Lymphoma, Large-Cell, Anaplastic
5
Lymphoma, B-Cell
5
Immunoblastic Lymphadenopathy
5
Burkitt Lymphoma
5
Interventions
Cisplatin
28
Pemetrexed
24
pembrolizumab
12
Nivolumab
10
Carboplatin
9
atezolizumab
7
Gemcitabine
7
Cyclophosphamide
7
durvalumab
6
Drug Therapy
6
sodium thiosulfate
5
Radiotherapy, Intensity-Modulated
5
tremelimumab
4
aldesleukin
4
Radiotherapy
4
Interleukin-2
4
sargramostim
3
Vinorelbine
3
Platinum
3
Photochemotherapy
3
Ipilimumab
3
Doxorubicin
3
Dihematoporphyrin Ether
3
Chemotherapy, Adjuvant
3
Cerebral Decortication
3
vatalanib
2
regorafenib
2
niraparib
2
lenvatinib
2
cemiplimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Mesothelioma, Malignant
×
Vorinostat
×
Clear all
NCT01353482
2012-03-22
MESO-02
University College, London
Phase 1/2
Withdrawn